This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mänttäri, M. Articles by Frick, M. H. Search for Related Content PubMed PubMed Citation Articles by Mänttäri, M. Articles by Frick, M. H.

(Hypertension. 1995;25:47-52.)
© 1995 American Heart Association, Inc.

Articles

Antihypertensive Therapy in Dyslipidemic Men

Effects on Coronary Heart Disease Incidence and Total Mortality

Matti Mänttäri; Leena Tenkanen; Vesa Manninen; Tiina Alikoski; M. H. Frick

From the First Department of Medicine, Helsinki (Finland) University.

Abstract To investigate the influence of antihypertensive therapy and the success of blood pressure control on coronary heart disease incidence and total mortality, we studied dyslipidemic middle-aged men participating in the placebo arm of the Helsinki Heart Study, a randomized coronary primary prevention trial with gemfibrozil. Based on blood pressure level and the presence of antihypertensive therapy at study entry, the participants were classified into four categories. Relative risks of coronary heart disease (nonfatal myocardial infarction or cardiac death) and total mortality during the 5-year trial period were calculated using Cox proportional hazards models. With subjects who were not using antihypertensive drugs and who had normal blood pressure (category I) as reference, the relative risks of coronary heart disease during the trial period were 2.1 (95% confidence interval [CI], 1.3 to 3.3) in untreated hypertensive subjects (category II), 0.9 (95% CI, 0.2 to 3.8) in subjects with successful antihypertensive therapy (category III), and 2.0 (95% CI, 1.0 to 4.1) in subjects who remained hypertensive despite drug therapy (category IV). The relative risks of death were 1.9 (95% CI, 0.9 to 3.9) in category II and 1.0 (95% CI, 0.1 to 7.3) in category III; in category IV subjects, those with unsuccessful antihypertensive therapy, the relative risk was 4.4 (95% CI, 2.0 to 9.6). The excess mortality in this category was due to cardiovascular causes and was clustered in subjects with multiple drug therapy for hypertension control. We conclude that successful antihypertensive therapy in dyslipidemic men reduced coronary heart disease incidence despite its adverse effects on high-density lipoprotein cholesterol and triglycerides. With regard to total mortality, adequate blood pressure reduction had a positive effect, and unsuccessful hypertension control increased total mortality, especially cardiovascular mortality.

Key Words: hypercholesterolemia • coronary heart disease • mortality • antihypertensive therapy

This article has been cited by other articles:

				H. Schunkert, H.-W. Hense, A. Gimenez-Roqueplo, J. Stieber, U. Keil, G. A.J. Riegger, and X. Jeunemaitre The Angiotensinogen T235 Variant and the Use of Antihypertensive Drugs in a Population-Based Cohort Hypertension, February 1, 1997; 29(2): 628 - 633. [Abstract] [Full Text]

				H. Bernardes-Silva, O. Toffoletto, L. A. Bortolotto, M. C.M. Latrilha, E. M. Krieger, F. Pileggi, and R. C. Maranhao Malignant Hypertension Is Accompanied by Marked Alterations in Chylomicron Metabolism Hypertension, December 1, 1995; 26(6): 1207 - 1210. [Abstract] [Full Text]